A New Approach to Assessing the Extent of Degradation of the Nigrostriatal Dopaminergic System in an Experimental Model of Parkinson’s Disease

2020 ◽  
Vol 50 (4) ◽  
pp. 451-458
Author(s):  
V. V. Safandeev ◽  
M. V. Ugrumov
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Experimental Model ◽  
Dopaminergic System ◽  
New Approach

Nanoemulsion Improves the Neuroprotective Effects of Curcumin in an Experimental Model of Parkinson’s Disease

2021 ◽  
Author(s):  
Osmar Vieira Ramires Júnior ◽  
Barbara da Silva Alves ◽  
Paula Alice Bezerra Barros ◽  
Jamile Lima Rodrigues ◽  
Shana Pires Ferreira ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Experimental Model ◽  
Neuroprotective Effects

Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson’s Disease

2016 ◽  
Vol 54 (2) ◽  
pp. 1513-1530 ◽  
Author(s):  
Danúbia Bonfanti Santos ◽  
Dirleise Colle ◽  
Eduardo Luiz Gasnhar Moreira ◽  
Mariana Appel Hort ◽  
Marcelo Godoi ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Experimental Model

scholarly journals Coordinating a new approach to basic research into Parkinson’s disease

eLife ◽  
2019 ◽  
Vol 8 ◽  
Author(s):  
Randy Schekman ◽  
Ekemini AU Riley
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Basic Research ◽  
Open Science ◽  
Research Community ◽  
International Network ◽  
New Approach ◽  
Science Practices ◽  
New Therapies

The Aligning Science Across Parkinson’s (ASAP) initiative is building an international network of researchers to improve our understanding of the biology underlying Parkinson's disease. Developing a better understanding of how the disease originates and progresses will, we hope, lead to new therapies. The ASAP initiative will incentivize collaboration between the existing PD research community and other researchers and will be committed to open-science practices.

scholarly journals Assessment of the Impacts of Selenocysteine on the Dopaminergic System in the Substantia Nigra and Striatum of 6-OHDA Parkinson's Disease Rat Model

IBRO Reports ◽  
2019 ◽  
Vol 7 ◽  
pp. 25
Author(s):  
A.F. Ibraheem ◽  
I.A. Ogeleyinbo ◽  
K.O. Emmanuel ◽  
E.V. Idar ◽  
J.O. Oyewale ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Substantia Nigra ◽  
Rat Model ◽  
Dopaminergic System

scholarly journals Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons

2011 ◽  
Vol 2011 ◽  
pp. 1-16 ◽  
Author(s):  
A. Machado ◽  
A. J. Herrera ◽  
J. L. Venero ◽  
M. Santiago ◽  
R. M. de Pablos ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Animal Model ◽  
Dopaminergic Neurons ◽  
Inflammatory Process ◽  
Dopaminergic System ◽  
Neuronal System ◽  
Dopamine Depletion ◽  
Anti Inflammatory ◽  
Dopaminergic Degeneration

We have developed an animal model of degeneration of the nigrostriatal dopaminergic neurons, the neuronal system involved in Parkinson's disease (PD). The implication of neuroinflammation on this disease was originally established in 1988, when the presence of activated microglia in the substantia nigra (SN) of parkinsonians was reported by McGeer et al. Neuroinflammation could be involved in the progression of the disease or even has more direct implications. We injected 2 μg of the potent proinflammatory compound lipopolysaccharide (LPS) in different areas of the CNS, finding that SN displayed the highest inflammatory response and that dopaminergic (body) neurons showed a special and specific sensitivity to this process with the induction of selective dopaminergic degeneration. Neurodegeneration is induced by inflammation since it is prevented by anti-inflammatory compounds. The special sensitivity of dopaminergic neurons seems to be related to the endogenous dopaminergic content, since it is overcome by dopamine depletion. Compounds that activate microglia or induce inflammation have similar effects to LPS. This model suggest that inflammation is an important component of the degeneration of the nigrostriatal dopaminergic system, probably also in PD. Anti-inflammatory treatments could be useful to prevent or slow down the rate of dopaminergic degeneration in this disease.

Sign in / Sign up

Export Citation Format

Share Document